Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 17/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.32 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.32 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.32 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30463653 | 1.00 | IDO1 (0.39) | IDO1HSD11B1GABRA1GABRG2GABRB3 | |
| SCHEMBL20474212 | 0.90 | IDO1 (0.35) | IDO1GABRA1GABRG2GABRB3GABRA3 | |
| SCHEMBL30829060 | 0.87 | IDO1 (0.38) | IDO1GABRA1GABRG2GABRB3GABRA3 | |
| SCHEMBL20474174 | 0.87 | IDO1 (0.38) | IDO1GABRA1GABRG2GABRB3GABRA3 | |
| SCHEMBL20474181 | 0.87 | IDO1 (0.34) | IDO1GABRA1GABRG2GABRB3GABRA3 | |
| SCHEMBL20474170 | 0.86 | IDO1 (0.35) | IDO1GABRA1GABRG2GABRB3GABRA3 | |
| SCHEMBL20474172 | 0.86 | IDO1 (0.33) | IDO1GABRA1GABRG2GABRB3GABRA3 | |
| SCHEMBL20474208 | 0.85 | GABRA1 (0.35) | IDO1GABRA1GABRG2GABRB3GABRA3 | |
| SCHEMBL20474225 | 0.84 | IDO1 (0.34) | IDO1GABRA1GABRG2GABRB3GABRA3 | |
| SCHEMBL20474190 | 0.84 | PIK3CA (0.35) | IDO1GABRA1GABRG2GABRB3GABRA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3929197-B1 | INTERMEDIATES FOR THE SYNTHESIS OF MICROBIOCIDAL HETEROBICYCLIC DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2024-03-06 | — | — | EP | disclosed |
| EP-3334736-B1 | MICROBIOCIDAL HETEROBICYCLIC DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2023-06-28 | — | — | EP | disclosed |
| EP-3929197-A1 | INTERMEDIATES FOR THE SYNTHESIS OF MICROBIOCIDAL HETEROBICYCLIC DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2021-12-29 | — | — | EP | disclosed |
| US-20210155619-A1 | MICROBIOCIDAL HETEROBICYCLIC DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2021-05-27 | — | — | US | disclosed |
| US-20210155619-A1 | MICROBIOCIDAL HETEROBICYCLIC DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2021-05-27 | — | — | US | disclosed |
| US-10906897-B2 | Microbiocidal heterobicyclic derivatives | SYNGENTA PARTICIPATIONS AG (CH) | 2021-02-02 | — | — | US | disclosed |
| US-10906897-B2 | Microbiocidal heterobicyclic derivatives | SYNGENTA PARTICIPATIONS AG (CH) | 2021-02-02 | — | — | US | disclosed |
| US-20180237434-A1 | MICROBIOCIDAL HETEROBICYCLIC DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2018-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10906897-B2 | Microbiocidal heterobicyclic derivatives | MSR1, C1R, C1S | IDO1 175/4885HSD11B1 4018/4885GABRA1 2310/4885 |
| US-20210155619-A1 | MICROBIOCIDAL HETEROBICYCLIC DERIVATIVES | CD14, MSR1, MPO | IDO1 618/4885HSD11B1 2049/4885GABRA1 1981/4885 |
| US-20180237434-A1 | MICROBIOCIDAL HETEROBICYCLIC DERIVATIVES | MSR1, C1R, C1S | IDO1 175/4885HSD11B1 4018/4885GABRA1 2310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.